Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial

The clinical utility of the 70-gene signature (MammaPrint ®) to guide chemotherapy use in T1-3N0-1M0 breast cancer was demonstrated in the Microarray in Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy (MINDACT) study. One thousand four ninety seven of 3356 (46.2%) enrolled patients with high clinical risk (in accordance with th e modified Adjuvant! Online clinical-pathological assessment) had a low-risk 70-gene signature. Using patient-level data from the MINDACT trial, the cost-effectiveness of using the 70-gene signature to guide adjuvant chemotherapy selection for clinical high risk, estrogen receptor positive (ER+), hu man epidermal growth factor 2 negative (HER2-) patients was analysed.

Source: European Journal of Cancer - August 10, 2020 Category: Cancer & Oncology Authors: Valesca P. Ret èl, Danalyn Byng, Sabine C. Linn, Katarzyna Jóźwiak, Hendrik Koffijberg, Emiel J. Rutgers, Fatima Cardoso, Martine J. Piccart, Coralie Poncet, Laura J. van't Veer, Wim H. van Harten Tags: Original Research Source Type: research